Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
First Claim
1. A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, said method comprising the steps of:
- providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, said liquid carrier comprising one or more lipophilic fluorochemicals and at least one nonfluorinated co-solvent; and
combining said stable pharmaceutical composition with an amount of at least one fluorochemical diluent less lipophilic than said one or more lipophilic fluorochemicals, said fluorochemical diluent present in an amount sufficient to initiate phase separation of said at least one lipophilic pharmaceutical agent from said pharmaceutical composition wherein a pharmaceutical microdispersion is formed.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the lipophilic pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.
124 Citations
63 Claims
-
1. A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, said method comprising the steps of:
-
providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, said liquid carrier comprising one or more lipophilic fluorochemicals and at least one nonfluorinated co-solvent; and combining said stable pharmaceutical composition with an amount of at least one fluorochemical diluent less lipophilic than said one or more lipophilic fluorochemicals, said fluorochemical diluent present in an amount sufficient to initiate phase separation of said at least one lipophilic pharmaceutical agent from said pharmaceutical composition wherein a pharmaceutical microdispersion is formed. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A high bioavailability pharmaceutical formulation comprising:
a substantially homogeneous microdispersion of a pharmaceutically effective amount of at least one lipophilic pharmaceutical agent in a liquid continuous phase, said liquid continuous phase comprising one or more physiologically acceptable lipophilic fluorochemicals, at least one nonfluorinated co-solvent and at least one fluorochemical diluent wherein the fluorochemical diluent is less lipophilic than the lipophilic fluorochemical, said substantially homogeneous microdispersion being formed upon combination of the fluorochemical diluent with the lipophilic fluorochemical. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 52, 53)
-
31. A method for delivering one or more lipophilic pharmaceutical agents to a physiologic target site, said method comprising the steps of:
-
providing a high bioavailability pharmaceutical formulation comprising a substantially homogeneous microdispersion of at least one lipophilic pharmaceutical agent in a liquid continuous phase, said liquid continuous phase comprising one or more lipophilic fluorochemicals, at least one nonfluorinated co-solvent and at least one fluorochemical diluent wherein the fluorochemical diluent is less lipophilic than the lipophilic fluorochemical, said substantially homogeneous microdispersion being formed upon combination of the fluorochemical diluent with the lipophilic fluorochemical; and introducing a pharmaceutically effective amount of said high bioavailability pharmaceutical formulation to a physiologic target site. - View Dependent Claims (32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A method for preparing a pharmaceutical material, comprising the steps of:
-
providing a pharmaceutical composition comprising a lipophilic first fluorochemical liquid, a nonfluorinated co-solvent and a pharmaceutical agent in a single continuous phase; and adding to said pharmaceutical composition a sufficient amount of a second fluorochemical liquid less lipophilic than said first fluorochemical liquid that is miscible in said first fluorochemical liquid, thereby causing phase separation of said pharmaceutical agent to form a microdisperse discontinuous phase. - View Dependent Claims (44, 45, 46, 47, 54, 55, 56, 57, 58, 63)
-
-
48. A method for providing a kit for preparing a pharmaceutical preparation, comprising:
-
placing a first composition comprising a first lipophilic liquid fluorocarbon, a nonfluorinated co-solvent and a pharmaceutical agent in a single continuous phase in a first container; and adding a second liquid fluorocarbon miscible with said first lipophilic liquid fluorocarbon to a second container, wherein said second liquid fluorocarbon is less lipophilic than said first lipophilic liquid fluorocarbon, such that upon combination of said first composition and said second liquid fluorocarbon, a phase separation of said pharmaceutical agent occurs to form a microdisperse discontinuous phase comprising said pharmaceutical agent. - View Dependent Claims (49, 50, 51, 59, 60, 61, 62)
-
Specification